Overview

Phase II Study of Gemcitabine Versus S-1 Adjuvant Therapy After Hemihepatectomy for Biliary Tract Cancer

Status:
Completed
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
To compare efficacy and safety of Gemcitabine versus S-1 adjuvant therapy after hemihepatectomy.
Phase:
Phase 2
Details
Lead Sponsor:
Kansai Hepatobiliary Oncology Group
Treatments:
Gemcitabine